Literature DB >> 21620504

Cervical nodal metastases of unresectable thoracic esophageal squamous cell carcinoma: characteristics of long-term survivors after concurrent chemoradiotherapy.

Hui Liu1, Lixia Lu, Qi Zhu, Yuantao Hao, Yunxian Mo, Mengzhong Liu, Yonghong Hu, Nianji Cui, Tiehua Rong.   

Abstract

PURPOSE: To analyze the clinical implications of metastatic cervical lymph nodes in unresectable thoracic esophageal squamous cell carcinoma (SCC) after concurrent chemoradiotherapy (CRT). METHODS AND MATERIALS: 208 thoracic esophageal SCC patients treated with concurrent CRT were analyzed retrospectively. Patients were divided into 3 groups according to different status of metastatic cervical lymph nodes: 1. CLN(-), no evidence of metastatic cervical lymph nodes; 2. CPLN(+), evidence of enlarged cervical paraesophageal lymph node without any other metastatic cervical lymph nodes; 3. OCLN(+), any other situations of enlarged cervical lymph nodes. The prognostic factors were examined univariately, then selected for inclusion in a multivariate Cox regression model.
RESULTS: Three-year OS of CLN(-),CPLN(+), and OCLN(+) groups were 39%, 33%, and 15% (logrank p=0.001). On univariate analysis, variables significantly associated with OS included sex, primary esophageal tumor location, length and cervical nodal disease. On multivariate analysis, primary tumor location (HR1.5, 95%CI 1.1-1.9, p=0.005), tumor length (HR1.5, 95%CI 1.1-2.0, p=0.010) and cervical nodal disease (HR1.2, 95%CI 1.0-1.5, p=0.014) were prognostic factors on OS.
CONCLUSIONS: (1) Primary tumor location, tumor length, and cervical nodal disease were significant prognostic factors on OS in esophageal SCC patients. (2) Patients with CPLN(+) disease tended to have a potential better long-term survival than those with OCLN(+) disease, and metastatic CPLN could be considered as local disease. The survival benefit in CPLN(+) subgroup might be contributed by the patients who presented with upper third thoracic tumors and shorter tumor length. Further investigation is needed.
Copyright © 2011. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21620504     DOI: 10.1016/j.radonc.2011.05.011

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  11 in total

1.  Relationship Between Clinicopathological Characteristics and PET/CT Uptake in Esophageal Squamous Cell Carcinoma: [18F]Alfatide versus [18F]FDG.

Authors:  Yinjun Dong; Yuchun Wei; Guanxuan Chen; Yong Huang; Pingping Song; Shuguang Liu; Jinsong Zheng; Monica Cheng; Shuanghu Yuan
Journal:  Mol Imaging Biol       Date:  2019-02       Impact factor: 3.488

2.  Association of insulin-like growth factor-binding protein-3 with radiotherapy response and prognosis of esophageal squamous cell carcinoma.

Authors:  Li-Ling Luo; Lei Zhao; Mian Xi; Li-Ru He; Jing-Xian Shen; Qiao-Qiao Li; Shi-Liang Liu; Peng Zhang; Dan Xie; Meng-Zhong Liu
Journal:  Chin J Cancer       Date:  2015-09-14

3.  Is there a benefit in receiving concurrent chemoradiotherapy for elderly patients with inoperable thoracic esophageal squamous cell carcinoma?

Authors:  Peng Zhang; Mian Xi; Lei Zhao; Jing-Xian Shen; Qiao-Qiao Li; Li-Ru He; Shi-Liang Liu; Meng-Zhong Liu
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

4.  Efficacy and prognostic analysis of chemoradiotherapy in patients with thoracic esophageal squamous carcinoma with cervical lymph nodal metastasis alone.

Authors:  Peng Zhang; Mian Xi; Lei Zhao; Qiao-Qiao Li; Li-Ru He; Shi-Liang Liu; Jing-Xian Shen; Meng-Zhong Liu
Journal:  Radiat Oncol       Date:  2014-11-26       Impact factor: 3.481

5.  The modified glasgow prognostic score is an independent prognostic factor in patients with inoperable thoracic esophageal squamous cell carcinoma undergoing chemoradiotherapy.

Authors:  Peng Zhang; Mian Xi; Qiao-Qiao Li; Li-Ru He; Shi-Liang Liu; Lei Zhao; Jing-Xian Shen; Meng-Zhong Liu
Journal:  J Cancer       Date:  2014-09-06       Impact factor: 4.207

6.  Regional hyperthermia combined with radiotherapy for esophageal squamous cell carcinoma with supraclavicular lymph node metastasis.

Authors:  Liming Sheng; Yongling Ji; Qiner Wu; Xianghui Du
Journal:  Oncotarget       Date:  2017-01-17

7.  Concurrent chemoradiotherapy combined with enteral nutrition support: a radical treatment strategy for esophageal squamous cell carcinoma patients with malignant fistulae.

Authors:  Li Ma; Guang-Yu Luo; Yu-Feng Ren; Bo Qiu; Hong Yang; Chun-Xia Xie; Song-Ran Liu; Shi-Liang Liu; Zhao-Lin Chen; Qun Li; Jian-Hua Fu; Meng-Zhong Liu; Yong-Hong Hu; Wen-Feng Ye; Hui Liu
Journal:  Chin J Cancer       Date:  2017-01-11

8.  Relationship between (18)F-fluorodeoxyglucose uptake in primary lesions and clinicopathological characteristics of esophageal squamous cell carcinoma patients.

Authors:  Mingping Sun; Baosheng Li; Zheng Fu; Yumei Wei; Jian Zhang; Hongfu Sun; Hongsheng Li; Rui Feng
Journal:  Exp Ther Med       Date:  2012-10-26       Impact factor: 2.447

9.  Unilateral cervical nodal metastasis is an independent prognostic factor for esophageal squamous cell carcinoma patients undergoing chemoradiotherapy: a retrospective study.

Authors:  Peng Zhang; Mian Xi; Lei Zhao; Qiao-Qiao Li; Liru He; Shiliang Liu; Jingxian Shen; Meng-Zhong Liu
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

10.  Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis.

Authors:  Peng Zhang; Mian Xi; Qiao-Qiao Li; Yong-Hong Hu; Xiaobo Guo; Lei Zhao; Hui Liu; Shi-Liang Liu; Li-Ling Luo; Qing Liu; Meng-Zhong Liu
Journal:  Oncotarget       Date:  2016-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.